Discovery and fine-mapping of difficult-to-treat asthma susceptibility loci to identify putative targets for drug development

Read full text Summarise with VIRAT
Authors: Noemi Nicole Piga
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Severe asthma represents ~3-10% of asthma patients and it is characterised by uncontrolled symptoms despite maximal treatment, representing an unmet clinical need. Genome-wide association study (GWAS) can disentangle the genomic risk factors for complex conditions. Previous attempts in asthma have focused on either general asthma or moderate-to-severe asthma, defined using self-reported medications. I leveraged recently released electronic health records (EHRs), performed a new GWAS, replicated the findings, and sought potential causal mechanisms in the context of severe asthma. In addition, I described how an asthma-associated locus can be validated using functional genomics.For my GWAS, I used prescriptions, death records, and hospitalisations to select asthma patients with ‘high treatment burden and/or loss of control’ in UK Biobank. This resulted in 7,681 cases and 38,405 sex and age-matched controls of European-like genetic ancestry. The case group included individuals not present in a previous moderate-to-severe asthma study, suggesting its added value.I replicated my GWAS in four additional cohorts, identifying twenty-one reproducibly associated sentinel variants (p-value < 5x10-6). These variants mapped to known general asthma loci, confirming shared genetic risk factors. Nevertheless, this phenotype conferred larger effect sizes than general asthma, suggesting a more genetically-driven subtype. I used fine-mapping to identify putative causal variants and a variant-to-gene mapping strategy to identify potential causal genes. Eighty-five genes were mapped, showing enrichment in inflammatory pathways and asthma-related cell-types. Five genes showed robust mapping evidence (BACH2, D2HGDH, IL1RL1, RPS26, SMAD3), indicating potential novel drug targets.Finally, I focused on in-vitro and in-silico approaches to validate causal variants upstream of the mucin gene MUC5AC, involved in moderate-to-severe asthma and respiratory diseases. The in-silico approach prioritised eight variants for functional studies. The in-vitro analysis was incomplete within the available time, but it demonstrated the feasibility of a functional genomics system to study GWAS variants.

Fields of Study & Subjects

Asthma and respiratory diseases Genetic Associations and Epidemiology Occupational exposure and asthma

Publication details

Journal / source
University of Leicester
Publication date
25 March 2026
Language
EN
Document type
Thesis